Madopar Capsules (Hard Gelatin)
Co-beneldopa (Benserazide, Levodopa)
"200mg, 50mg"
F. Hoffmann-La Roche Ltd.
| Pack size | 100's |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | IBN KHALDOON DRUG STORE |
| Retail Price | 205.50 AED |
Available as:
Indications
Madopar Capsules (Hard Gelatin) is used for:
BENSERAZIDE
It is used in the management of parkinson's disease in combination with l-dopa (levodopa) as co-beneldopa. These combinations are also used for the treatment of restless legs syndrome
CARBIDOPA
For treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
It is used in the management of parkinson's disease in combination with l-dopa (levodopa) as co-beneldopa. These combinations are also used for the treatment of restless legs syndrome
CARBIDOPA
For treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Co-beneldopa (Benserazide, Levodopa) :
Mechanism of Action
BENSERAZIDE
Levodopa is a precursor to the neurotransmitter dopamine which is administered to increase its levels in the central nervous system. However, most levodopa is decarboxylated to dopamine before it reaches the brain, and since dopamine is unable to cross the blood?brain barrier, this translates to little therapeutic gain with strong peripheral side effects. Benserazide inhibits the aforementioned decarboxylation, and since it itself cannot cross the blood?brain barrier, this allows dopamine to build up solely in the brain instead
CARBIDOPA
When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine and the decarboxylation of oxitriptan to serotonin by aromatic l-amino acid decarboxylase. This results in increased amount of levodopa and oxitriptan available for transport to the cns. Carbidopa also inhibits the metabolism of levodopa in the gi tract, thus, increasing the bioavailability of levodopa
Levodopa is a precursor to the neurotransmitter dopamine which is administered to increase its levels in the central nervous system. However, most levodopa is decarboxylated to dopamine before it reaches the brain, and since dopamine is unable to cross the blood?brain barrier, this translates to little therapeutic gain with strong peripheral side effects. Benserazide inhibits the aforementioned decarboxylation, and since it itself cannot cross the blood?brain barrier, this allows dopamine to build up solely in the brain instead
CARBIDOPA
When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine and the decarboxylation of oxitriptan to serotonin by aromatic l-amino acid decarboxylase. This results in increased amount of levodopa and oxitriptan available for transport to the cns. Carbidopa also inhibits the metabolism of levodopa in the gi tract, thus, increasing the bioavailability of levodopa
Note
Madopar "200mg, 50mg" Capsules (Hard Gelatin) manufactured by F. Hoffmann-La Roche Ltd.. Its generic name is Co-beneldopa (Benserazide, Levodopa). Madopar is availble in United Arab Emirates.
Farmaco UAE drug index information on Madopar Capsules (Hard Gelatin) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.